- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03383601
Сohort Study to Evaluate Exacerbations, Respiratory Symptoms, Physical Exercise Intolerance and Lung Functions Among Participants Who Use IQOS With Heatsticks Compared to Smokers of Conventional Cigarettes
A 5-year Cohort Observational Study to Evaluate Frequency of Exacerbations, Respiratory Symptoms, Physical Exercise Intolerance and Abnormal Lung Functions Among Participants Who Use IQOS With Heatsticks Compared to Smokers of Conventional Cigarettes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heated Tobacco Products, such as Heatsticks heated by iQOS device, are specially designed tobacco products that contain tobacco material and several filter sections. Recent studies demonstrate that the vapor from Heatsticks heated by iQOS device contains 90 to 95% less harmful and potentially harmful compounds ("HPHCs") and is 90 to 95% less toxic than the smoke of a reference combustible cigarette.
IQOS with HeatSticks may serve as less risky alternatives to combustible cigarettes and to other traditional tobacco products in clinical setting. The investigators hypothesize that participants using IQOS with HeatSticks will have less prevalent presence of respiratory symptoms, have better functional exercise capacity, and experience less exacerbations compared to those who smoke combustible cigarettes by demonstrating whether the trends of the response variables across time is the same between the exposure and the control groups.
This 5-years observational study includes two cohorts of participants age 40 - 59: (1) smokers of combustible cigarettes (CC smokers -control group) and (2) users of IQOS with HeatStick (exposure group). The study has baseline and periodic (annual) comprehensive clinical assessments, as well as continuous COPD case-finding activities and registering acute exacerbations of COPD.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Almaty, Kazakhstan, 050008
- Kazakhstan Academy of Preventive Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female
- Age 40-59 years inclusive
- Smoking history ≥10 pack-years (for both cohorts)
- Ability to follow study procedures
Exclusion Criteria:
Pregnant women; Legally incapable individuals;
Patients with history of:
- chronic infectious and non-infectious lung disease except asthma (e.g. pulmonary fibrosis, bronchiectasis, cystic fibrosis, tuberculosis, etc.) diagnosed prior to or during the first visit to KAPM COPD Center;
- previous surgical excision of at least one lung lobe (or having undergone a lung volume reduction procedure);
- active cancer of any localization under treatment;
- suspected cancer of any localization;
- metallic articles in the chest;
- recent eye surgery (during the last 6 month prior to the visit);
- episode (s) of myocardial infarction within less than 6 months prior to the visit or another form of acute or chronic coronary heart disease, history of heart rhythm abnormality with episode of arrhythmia within the last 6 months prior to the visit or long lasting that requires continuous drug therapy;
- acute episode of cerebrovascular ischemic attack within the last 12 month prior to the visit;
- chest or abdominal surgery performed within the last 6 month prior the visit;
- contraindications to salbutamol or refusal to inhale salbutamol;
- chest radiation therapy within the last 12 month prior to the visit; radiology diagnostic procedures of chest within the last 6 months prior to the visit;
- recent (6 weeks before the visit) respiratory tract infection (colds, flus), fever of any etiology with increasing temperature over 37 C at the time of the visit and in the last 2 weeks prior to the visit;
- significant history of alcohol abuse or consumption of more than recommended units of alcohol per week (28 units male and 21 units female);
- positive screening test for HIV antibodies or positive screening for TB, if available at the time of first visit;
- elevated blood pressure (systolic) is ≥160 mmHg at the moment of visit. PMI employees and first degree relatives
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Users of IQOS with HeatStick
Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
|
Heated Tobacco Products: heatsticks heated by iQOS device
|
Smokers of combustible cigarettes
Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
|
Current smoking of combustible cigarettes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of respiratory symptoms defined by CAT≥10
Time Frame: 5 years
|
The total COPD Assessment Test Scores 10 and more as an indicator of more symptoms
|
5 years
|
Functional exercise incapacity
Time Frame: 5 years
|
Less than 450 meters walked during the six-minute walk test
|
5 years
|
Respiratory exacerbations
Time Frame: 5 years
|
A worsening of respiratory symptoms, which required treatment with oral corticosteroids or antibiotics, or both or a health care utilization event (office visit, hospital admission, or emergency department visit for a respiratory flare-up).
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence of chronic obstructive pulmonary disease
Time Frame: 5 years
|
Airflow obstruction based on the fixed ratio of post-bronchodilator FEV1 /FVC < 0.70 criterion
|
5 years
|
ECG abnormalities
Time Frame: 5 years
|
Presence of any ECG abnormalities including pathologic q-waves, ST elevation, ST depression, T-wave inversion, hypertrophy, QRS axis deviation, block, arrhythmia.
|
5 years
|
Clinical findings by physical pulmonary exam
Time Frame: 5 years
|
Presence of any pathological findings during the pulmonary (percussion and inspection) exam
|
5 years
|
Clinical findings by physical cardiac second sounds exams
Time Frame: 5 years
|
Presence of any pathological findings during the cardiac second sounds exam
|
5 years
|
Metabolic syndrome
Time Frame: 5 years
|
Presence of metabolic syndrome based on the IDF definition: Central obesity (defined as waist circumference with ethnicity specific values) PLUS any two of the following four factors: raised triglycerides; reduced HDL cholesterol; raised blood pressure; raised fasting plasma glucose
|
5 years
|
Decreased Oxygen saturation
Time Frame: 5 years
|
Percentage of hemoglobin loaded with oxygen (<95%)
|
5 years
|
Low Dose Computerised Tomography (LDCT) of the Chest Features
Time Frame: 5 years
|
Grading the severity of the following: bronchiectasis, bronchial wall thickening, emphysema, reticular pattern or honeycombing.
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Almaz Sharman, MD, PhD, Kazakhstan Academy of Preventive Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMI.IIS.2016.1.1.
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Heated Tobacco product IQOS/heatstick
-
Medical University of South CarolinaCompleted
-
Semmelweis UniversityCompleted
-
Karolinska InstitutetSwedish Heart Lung FoundationCompleted
-
Imperial Brands PLCCompleted
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
-
Institute of Cardiology, Warsaw, PolandPMPSANot yet recruitingCoronary Artery Disease | Nicotine Dependence | Coronary AtherosclerosisPoland
-
Imperial Brands PLCRecruitingHealthy VolunteersUnited Kingdom
-
University of RijekaCroatian Science FoundationCompleted
-
Philip Morris Products S.A.Terminated
-
Philip Morris Products S.A.Terminated